GDRX Stock Recent News

GoodRx Holdings, Inc. (NASDAQ:GDRX ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Aubrey Reynolds - Director of Investor Relations Scott Wagner - Interim Chief Executive Officer Karsten Voermann - Chief Financial Officer Mike Walsh - President & EVP, Prescription Marketplace Conference Call Participants Charles Rhyee - TD Cowen Lisa Gill - JPMorgan John Ransom - Raymond James Stephanie Davis - Barclays Jailendra Singh - Truist Securities Scott Schoenhaus - KeyBanc Stan Berenshteyn - Wells Fargo Securities Kevin Caliendo - UBS Allen Lutz - Bank of America Daniel Grosslight - Citi Jack Wallace - Guggenheim Securities George Hill - Deutsche Bank Operator Ladies and gentlemen, thank you for standing by, and welcome to the Rx Second Quarter 2024 Earnings Call. As a reminder, today's conference call is being recorded.

Prescription savings platform GoodRx Holdings Inc. GDRX reported second-quarter revenue of $200.61 million, up 6% year over year, almost in line with the consensus of $200.4 million.

Although the revenue and EPS for GoodRx (GDRX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading prescription savings platform in the U.S., has released its financial results for the second quarter of 2024. Second Quarter 2024 Highlights Revenue1 and Adjusted Revenue1 of $200.6 million Net income of $6.7 million; Net income margin of 3.3% Adjusted Net Income1 of $32.4 million; Adjusted Net Income Margin1 of 16.1% Adjusted EBITDA1 of $65.4 million; Adjuste.

Besides Wall Street's top -and-bottom-line estimates for GoodRx (GDRX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.

GoodRx stock rated a sell due to industry headwinds, cost growth outpacing revenue, and needing 12%+ growth to justify price. Q2 earnings expected to be in line with guidance, but long-term guidance doesn't support current price point. Upside potential if GoodRx doubles market growth, but industry headwinds and growth struggles pose challenges.

First biosimilar with an exclusive low cash price on the GoodRx platform RIDGEFIELD, Conn. and SANTA MONICA, Calif.

Investors with an interest in Medical Services stocks have likely encountered both Icon PLC (ICLR) and GoodRx Holdings, Inc. (GDRX). But which of these two stocks is more attractive to value investors?

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced it will release its second quarter 2024 financial results before U.S. markets open on Thursday, August 8, 2024. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference.